NCT03223779View on ClinicalTrials.gov

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

TAS-102

Trifluridine stops DNA replication which may prevent the cancer cells from growing

RADIATION

Photon SBRT

SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells

Trial Locations (1)

02215

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Taiho Oncology, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER